1. Flydal MI, Martinez A. Phenylalanine hydroxylase: function, structure, and regulation. IUBMB Life 2013;65(4):341-9. http://dx.doi.org/10.1002/iub.1150 [
DOI:10.1002/iub.1150] [
PMID]
2. Herenger Y, Maes E, François L, Pasco J, Bouchereau J, Pichard S, et al. Determining factors of the cognitive outcome in early treated PKU: A study of 39 pediatric patients. Mol Genet Metab Rep 2019;20(100498):100498. http://dx.doi.org/10.1016/j.ymgmr.2019.100498 [
DOI:10.1016/j.ymgmr.2019.100498] [
PMID] [
]
3. van Spronsen FJ, Blau N, Harding C, Burlina A, Longo N, Bosch AM. Phenylketonuria. Nat Rev Dis Primers 2021;7(1):36. http://dx.doi.org/10.1038/s41572-021-00267-0 [
DOI:10.1038/s41572-021-00267-0] [
PMID] [
]
4. Moyle JJ, Fox AM, Arthur M, Bynevelt M, Burnett JR. Meta-analysis of neuropsychological symptoms of adolescents and adults with PKU. Neuropsychol Rev 2007;17(2):91-101. http://dx.doi.org/10.1007/s11065-007-9021-2 [
DOI:10.1007/s11065-007-9021-2] [
PMID]
5. Burgard P. Development of intelligence in early treated phenylketonuria. Eur J Pediatr 2000;159 Suppl 2:S74-9. http://dx.doi.org/10.1007/pl00014388 [
DOI:10.1007/PL00014388] [
PMID]
6. Fonnesbeck CJ, McPheeters ML, Krishnaswami S, Lindegren ML, Reimschisel T. Estimating the probability of IQ impairment from blood phenylalanine for phenylketonuria patients: a hierarchical meta-analysis. J Inherit Metab Dis 2013;36(5):757-66. http://dx.doi.org/10.1007/s10545-012-9564-0 [
DOI:10.1007/s10545-012-9564-0] [
PMID]
7. Koch R, Burton B, Hoganson G, Peterson R, Rhead W, Rouse B, et al. Phenylketonuria in adulthood: A collaborative study. J Inherit Metab Dis 2002;25(5):333-46. http://dx.doi.org/10.1023/a:1020158631102 [
DOI:10.1023/A:1020158631102] [
PMID]
8. Heidari A, Arab M, Etemad K, Damari B, Lotfi M. National Phenylketonuria Screening Program in Iran; Why and How? Sci J Schf Pub Health Instit Pub Health Res 2018;16(2):148-63. [
Google Scholar]
9. Daneshi S, Takaloo M, Davarani R, Heidarabadi M. Rezabeigi Davarani E. Incidence of phenylketonuria and the effect of prevention national program on reducing its incidence in the population covered by Kerman University of Medical Sciences during. Iran J Obstet Gynecol Infertil 2007;24(13):59-69. [
Google Scholar]
10. Sadek AA, Hassan MH, Mohammed NA. Clinical and neuropsychological outcomes for children with phenylketonuria in Upper Egypt; a single-center study over 5 years. Neuropsychiatr Dis Treat 2018;14:2551-61. http://dx.doi.org/10.2147/NDT.S176198 [
DOI:10.2147/NDT.S176198] [
PMID] [
]
11. Khemir S, Halayem S, Azzouz H, Siala H, Ferchichi M, Guedria A, et al. Autism in phenylketonuria patients: From clinical presentation to molecular defects: From clinical presentation to molecular defects. J Child Neurol 2016;31(7):843-9. http://dx.doi.org/10.1177/0883073815623636 [
DOI:10.1177/0883073815623636] [
PMID]
12. Saad K, Elserogy Y, Abdel Rahman AA, Al-Atram AA, Mohamad IL, ElMelegy TTH, et al. ADHD, autism and neuroradiological complications among phenylketonuric children in Upper Egypt. Acta Neurol Belg 2015;115(4):657-63. http://dx.doi.org/10.1007/s13760-014-0422-8 [
DOI:10.1007/s13760-014-0422-8] [
PMID]
13. Koch R, Moseley K, Ning J, Romstad A, Guldberg P, Guttler F. Long-term beneficial effects of the phenylalanine-restricted diet in late-diagnosed individuals with phenylketonuria. Mol Genet Metab 1999;67(2):148-55. http://dx.doi.org/10.1006/mgme.1999.2863 [
DOI:10.1006/mgme.1999.2863] [
PMID]
14. Potocnik U, Widhalm K. Long-term follow-up of children with classical phenylketonuria after diet discontinuation: a review. J Am Coll Nutr 1994;13(3):232-6. http://dx.doi.org/10.1080/07315724.1994.10718402 [
DOI:10.1080/07315724.1994.10718402] [
PMID]
15. Janzen D, Nguyen M. Beyond executive function: non-executive cognitive abilities in individuals with PKU. Mol Genet Metab 2010;99 Suppl 1:S47-51. http://dx.doi.org/10.1016/j.ymgme.2009.10.009 [
DOI:10.1016/j.ymgme.2009.10.009] [
PMID]
16. Waisbren SE, Noel K, Fahrbach K, Cella C, Frame D, Dorenbaum A, et al. Phenylalanine blood levels and clinical outcomes in phenylketonuria: a systematic literature review and meta-analysis. Mol Genet Metab 2007;92(1-2):63-70. http://dx.doi.org/10.1016/j.ymgme.2007.05.006 [
DOI:10.1016/j.ymgme.2007.05.006] [
PMID]
17. Michel U, Schmidt E, Batzler U. Results of psychological testing of patients aged 3-6 years. Eur J Pediatr 1990;149 Suppl 1:S34-8. http://dx.doi.org/10.1007/bf02126297 [
DOI:10.1007/BF02126297] [
PMID]
18. Brumm VL, Grant ML. The role of intelligence in phenylketonuria: a review of research and management. Mol Genet Metab 2010;99 Suppl 1:S18-21. http://dx.doi.org/10.1016/j.ymgme.2009.10.015 [
DOI:10.1016/j.ymgme.2009.10.015] [
PMID]
19. Welsh M, Deroche K, Gilliam DA. Neurocognitive models of early-treated Phenylketonuria: insights from meta-analysis and new molecular genetic findings. Handb Dev Cogne Neurosci 2008;2:677-89. [
Google Scholar]
20. Ris MD, Williams SE, Hunt MM, Berry HK, Leslie N. Early-treated phenylketonuria: adult neuropsychologic outcome. J Pediatr 1994;124(3):388-92. http://dx.doi.org/10.1016/s0022-3476(94)70360-4 [
DOI:10.1016/S0022-3476(94)70360-4] [
PMID]
21. Luciana M, Sullivan J, Nelson CA. Associations between phenylalanine‐to‐tyrosine ratios and performance on tests of neuropsychological function in adolescents treated early and continuously for phenylketonuria. Child Dev 2001;72(6):1637-52. http://dx.doi.org/10.1111/1467-8624.00370 [
DOI:10.1111/1467-8624.00370] [
PMID]
22. Weglage J, Pietsch M, Fünders B, Koch H, Ullrich K. Deficits in selective and sustained attention processes in early treated children with phenylketonuria-result of impaired frontal lobe functions? Eur J Pediatr 1996;155:200-4. [
DOI:10.1007/BF01953938] [
PMID]